- Reata Pharmaceuticals ( NASDAQ: RETA ) on Thursday said the U.S. FDA had informed the company that it was not planning to hold an advisory committee meeting for the review of its new drug application for its Friedreich's ataxia treatment.
- The company is developing an investigational activator called omaveloxolone for the treatment of the rare, genetic neuromuscular disorder.
- The treatment has previously received U.S. FDA orphan drug, fast track and rare pediatric disease designations.
- Class A shares of RETA earlier closed +2.6% at $25.05.
For further details see:
FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug